Business Description
Helix BioPharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA4229101098
Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.31 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.8 | |||||
| 3-Year EPS without NRI Growth Rate | 24.7 | |||||
| 3-Year FCF Growth Rate | 30.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.71 | |||||
| 9-Day RSI | 97.1 | |||||
| 14-Day RSI | 92.95 | |||||
| 6-1 Month Momentum % | 9.77 | |||||
| 12-1 Month Momentum % | 6.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.74 | |||||
| Quick Ratio | 0.74 | |||||
| Cash Ratio | 0.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.7 | |||||
| Shareholder Yield % | -6.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42645.83 | |||||
| ROA % | -511.75 | |||||
| ROIC % | -2486.59 | |||||
| 3-Year ROIIC % | 396.88 | |||||
| ROC (Joel Greenblatt) % | -16788.46 | |||||
| ROCE % | -43035.21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -10.36 | |||||
| EV-to-EBITDA | -10.39 | |||||
| EV-to-FCF | -10.61 | |||||
| Earnings Yield (Greenblatt) % | -9.65 | |||||
| FCF Yield % | -7.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HBPCD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helix BioPharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.159 | ||
| Beta | -0.03 | ||
| Volatility % | 22.87 | ||
| 14-Day RSI | 92.95 | ||
| 14-Day ATR ($) | 0.011029 | ||
| 20-Day SMA ($) | 0.78244 | ||
| 12-1 Month Momentum % | 6.97 | ||
| 52-Week Range ($) | 0.6885 - 0.9143 | ||
| Shares Outstanding (Mil) | 49.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Helix BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helix BioPharma Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Helix BioPharma Corp Frequently Asked Questions
What is Helix BioPharma Corp(HBPCD)'s stock price today?
The current price of HBPCD is $0.91. The 52 week high of HBPCD is $0.91 and 52 week low is $0.69.
When is next earnings date of Helix BioPharma Corp(HBPCD)?
The next earnings date of Helix BioPharma Corp(HBPCD) is .
Does Helix BioPharma Corp(HBPCD) pay dividends? If so, how much?
Helix BioPharma Corp(HBPCD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers